PROGRAM CHAIR
Matthew P. Wicklund, MD
Professor of Neurology
Vice Chair for Research
Department of Neurology
UT Health San Antonio
San Antonio, TX
Faculty
Aravindhan Veerapandiyan, MD
Associate Professor of Pediatrics
University of Arkansas for Medical Sciences
Director Comprehensive Neuromuscular Program
Arkansas Children’s Hospital
Little Rock, AR
PROGRAM OVERVIEW
This educational activity is designed for neurologists and associated health care practitioners (HCPs) including neuromuscular specialists, pediatric and developmental neurologists, pediatricians, geneticists, physical and occupational therapists, nurse practitioners and physicians’ assistants, that are involved in the management of patients with limb girdle muscular dystrophy (LGMD). Specifically, the program will help HCPs assess the burden of LGMD to help justify the medical need for development of a viable therapy for patients whose only current alternative is supportive care. The program will introduce various investigational therapies for the treatment of LGMD and also help HCPs incorporate genetic testing as a routine procedure into the diagnostic process.
TARGET AUDIENCE
This activity is intended for general neurologists, particularly those that see older patients, pediatric and developmental neurologists, neuromuscular specialists, pediatricians, geneticists, genetic counsellors, physical and occupational therapists, nurse practitioners, and physician assistants involved in the management of patients with limb girdle muscular dystrophy (LGMD).
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Assess the burden of illness associated with LGMDs
- Incorporate genetic testing into the diagnostic process for LGMD
- Justify the medical need to develop a viable therapy for patients with LGMD, for whom supportive care is presently the only available option
- Evaluate the investigational therapies for the treatment of LGMD
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationships | Manufacturer |
| Matthew P. Wicklund, MD | Consultant | Amicus Therapeutics, Lupin, ML Bio Solutions, Sarepta Therapeutics, Spark Therapeutics, UCB, Ultragenyx |
| Contracted Research | Avidity, Edgewise, Fulcrum, Harmony, ML Bio, Sarepta Therapeutics | |
| Aravindhan Veerapandiyan, MD | Consultant/Advisory Board | AMO Pharma, AveXis, Biogen, Edgewise Therapeutics, FibroGen, Novartis, Pfizer, PTC Therapeutics, Sarepta Therapeutics, UCB Pharma, Catalyst, Lupin, Entrada, Italfarmaco, and Scholar Rock |
| Contracted Research | AMO Pharma, Capricor Therapeutics, Edgewise Therapeutics, FibroGen, Muscular Dystrophy Association, Novartis, Parent Project Muscular Dystrophy, Pfizer, RegenxBio, and Sarepta Therapeutics | |
| Editorial Services | MedLink Neurology |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Vaidehee Deshpande, Medical Director for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 28, 2024
EXPIRATION DATE: June 28, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
